Presage Biosciences and Millennium: The Takeda Oncology Co. signed a research deal to identify novel cancer drug combinations for treatment of solid tumors. The agreement gives Millennium access to Presage's technology that allows multiple threads of drug candidates to be placed directly into a tumor. Presage will receive an upfront payment and research funding, plus development and regulatory milestone fees.

Related Summaries